Literature DB >> 29845218

Elevated TFAP4 regulates lncRNA TRERNA1 to promote cell migration and invasion in gastric cancer.

Huazhang Wu1, Xiufang Liu1, Pihai Gong1, Wei Song1, Menghan Zhou1, Yiping Li2, Zhujiang Zhao1, Hong Fan1.   

Abstract

Cancer cell invasion and metastasis are the leading causes of the high mortality rates in patients with malignant tumors. There is accumulating evidence to indicate that dysregulated long non‑coding RNAs (lncRNAs) may be involved in the progression of tumor invasion and metastasis. However, the regulatory mechanisms of the aberrant expression of lncRNAs remain largely unknown, although the roles of lncRNAs as drivers of tumor suppressive and oncogenic functions have appeared in prevalent cancer types in recent years. In the present study, we identified that the transcription factor, activating enhancer‑binding protein 4 (TFAP4), acts as a key modulator of translation regulatory long non‑coding RNA 1(TRERNA1), which has been proven to promote the invasion and metastasis of gastric cancer (GC) cells. We revealed that TRERNA1 was upregulated in gastric carcinogenesis and promoted cell migration and invasion in GC. Using bioinformatics analysis, we observed that there were several potential binding sites of TFAP4 in the promoter region of TRERNA1. The knockdown of TFAP4 significantly reduced the expression level of TRERNA1, whereas the ectopic expression of TFAP4 significantly increased the expression level of TRERNA1 in GC cell lines. Dual luciferase reporter assay combined with chromatin immunoprecipitation (ChIP) revealed that TFAP4 specifically regulated the transcriptional activity of TRERNA1 by binding to the E‑box motifs in the TRERNA1 promoter. In addition, there was a positive correlation between the TFAP4 and TRERNA1 expression level in clinical GC cases, which also indicated that TFAP4 can directly modulate the expression of TRERNA1. In the present study, we provide a novel potential therapeutic target and strategy for GC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29845218     DOI: 10.3892/or.2018.6466

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  MicroRNA-608 Promotes Apoptosis in Non-Small Cell Lung Cancer Cells Treated With Doxorubicin Through the Inhibition of TFAP4.

Authors:  Yi-Fei Wang; Xiang Ao; Ying Liu; Dan Ding; Wen-Jie Jiao; Zhuang Yu; Wen-Xin Zhai; Sheng-Hua Dong; Yu-Qi He; Hang Guo; Jian-Xun Wang
Journal:  Front Genet       Date:  2019-09-10       Impact factor: 4.599

Review 2.  Transcription Factor AP4 Mediates Cell Fate Decisions: To Divide, Age, or Die.

Authors:  Matthew Man-Kin Wong; Sancy Mary Joyson; Heiko Hermeking; Sung Kay Chiu
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

3.  Identification hub genes of consensus molecular subtype correlation with immune infiltration and predict prognosis in gastric cancer.

Authors:  Xin Yu; Bin Yu; Weidan Fang; Jianping Xiong; Mei Ma
Journal:  Discov Oncol       Date:  2021-10-16

4.  Upregulating microRNA-373-3p promotes apoptosis and inhibits metastasis of hepatocellular carcinoma cells.

Authors:  Hongbin Li; Nan Wang; Yuntian Xu; Xiao Chang; Jing Ke; Jun Yin
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

5.  Inhibitory effect of CC chemokine ligand 23 (CCL23)/ transcription factor activating enhancer binding protein 4 (TFAP4) on cell proliferation, invasion and angiogenesis in hepatocellular carcinoma.

Authors:  Weiwei Wang; Jianjun Wu; Xulei Dai; Kun Cheng
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

6.  Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer.

Authors:  Xi Liu; Xiaodong Wei; Wei Niu; Dong Wang; Bo Wang; Hao Zhuang
Journal:  Mol Med Rep       Date:  2018-09-07       Impact factor: 2.952

7.  Silencing of the Long Non-Coding RNA TTN-AS1 Attenuates the Malignant Progression of Osteosarcoma Cells by Regulating the miR-16-1-3p/TFAP4 Axis.

Authors:  Xianghai Meng; Zhenjun Zhang; Lin Chen; Xi Wang; Qingguo Zhang; Shuheng Liu
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.